Download PDF
Exp Clin Endocrinol Diabetes 2004; 112(7): 390-394
DOI: 10.1055/s-2004-821024
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

A Stable Prostacyclin Analogue Reduces High Serum TNF-α Levels in Diabetic Patients

K. Fujiwara1 , A. Nagasaka1 , M. Nagata1 , K. Yamamoto1 , S. Imamura1 , N. Oda1 , Y. Sawai1 , N. Hayakawa1 , A. Suzuki1 , M. Itoh1
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan
Further Information

Publication History

Received: July 9, 2003 First decision: September 15, 2003

Accepted: December 8, 2003

Publication Date:
07 July 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Aims: To confirm whether a prostacyclin (prostaglandin I2) affects the increased TNF-α concentration in sera of diabetic patients, we measured serum TNF-α concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy.

Subjects and Methods: Serum TNF-α concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-α.

Results: In diabetic patients, serum TNF-α concentration was significantly increased compared with that of healthy subjects. The augmented TNF-α concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin I2) analogue for 5 weeks without any changes of blood glucose levels.

Conclusions: Stable prostacyclin analogue administration for a short term period reduced increased TNF-α levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.

Key words

Prostacyclin (prostaglandin I2) - diabetes mellitus - tumor necrosis factor-α (TNF-α)

References

  • 1 Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C, Coppo R. Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells.  Kidney Int. 1997;  51 27-35
    PubMedSearch in Google Scholar
  • 2 Askari B, Ferreri N R. Regulation of prostacyclin synthesis by angiotensin II and TNF-alpha in vascular smooth muscle.  Prostaglandins Other Lipid Mediat. 2001;  63 175-187
    CrossrefPubMedSearch in Google Scholar
  • 3 Benjafield A V, Glenn C L, Wang X L, Colagiuri S, Morris B J. TNFRSF1 B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes.  Diabetes Care. 2001;  24 753-757
    PubMedSearch in Google Scholar
  • 4 Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes.  Eur J Endocrinol. 2002;  146 325-331
    CrossrefPubMedSearch in Google Scholar
  • 5 Coughlan M T, Oliva K, Georgiou H M, Permezel J M, Rice G E. Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus.  Diabetic Med. 2001;  18 921-927
    CrossrefPubMedSearch in Google Scholar
  • 6 Crutchley D J, Conanan L B, Que B G. Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells.  J Pharmacol Exp Therp. 1994;  271 446-451
    PubMedSearch in Google Scholar
  • 7 Garvey W T, Maianu L, Zhu J H, Hancock J A, Golichowski A M. Multiple defects in the adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes. Heterogeneity in the number and a novel abnormality in subcellular localization of GLUT4 glucose transporters.  Diabetes. 1993;  42 1773-1785
    PubMedSearch in Google Scholar
  • 8 Hart P H, Whitty G A, Piccoli D S, Hamilton J A. Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes.  Immunology. 1989;  66 376-383
    PubMedSearch in Google Scholar
  • 9 Haynes D R, Whitehouse M W, Vernon-Roberts B. The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3.  Immunology. 1992;  76 251-257
    PubMedSearch in Google Scholar
  • 10 Hotamisligil G S, Arner P, Caro J F, Atkinson R L, Spiegelman B M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.  J Clin Invest. 1995;  95 2409-2415
    CrossrefPubMedSearch in Google Scholar
  • 11 Hotamisligil G S, Peraldi P, Budavari A, Ellis R, White M F, Spiegelman B M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.  Science. 1996;  271 665-668
    CrossrefPubMedSearch in Google Scholar
  • 12 Hotamisligil G S, Shargill N S, Spiegelman B M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.  Science. 1993;  259 87-91
    CrossrefPubMedSearch in Google Scholar
  • 13 Hotamisligil G S, Spiegelman B M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link.  Diabetes. 1994;  43 1271-1278
    CrossrefPubMedSearch in Google Scholar
  • 14 Kainoh M, Maruyama I, Nishio S, Nakadate T. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level.  Biochem Pharmacol. 1991;  41 1135-1140
    CrossrefPubMedSearch in Google Scholar
  • 15 Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor are increased in obese patients with noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1998;  83 859-862
    CrossrefPubMedSearch in Google Scholar
  • 16 Kern P A, Saghizadeh M, Ong J M, Bosch R J, Deem R, Simsolo R B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.  J Clin Invest. 1995;  95 2111-2119
    CrossrefPubMedSearch in Google Scholar
  • 17 Kunkel S L, Spengler M, May M A, Spengler R, Larrick J, Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.  J Biol Chem. 1988;  263 5380-5384
    PubMedSearch in Google Scholar
  • 18 Langeler E G, Fiers W, van Hinsbergh V W. Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers.  Arteriosclerosis & Thrombosis. 1991;  11 872-881
    PubMedSearch in Google Scholar
  • 19 Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances.  Annl NY Acad Sciences. 1999;  892 146-154
    CrossrefPubMedSearch in Google Scholar
  • 20 McCarty M F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline.  Med Hypotheses. 1999;  52 465-477
    PubMedSearch in Google Scholar
  • 21 Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor- and insulin resistance in obese men with Type 2 diabetes mellitus.  Diabetes Res Clin Prac. 2001;  52 119-123
    CrossrefPubMedSearch in Google Scholar
  • 22 Nishimura S, Satoh J, Toyota T. Serum TNF α levels and diabetic complications in NIDDM patients.  Diabetologia. 1997;  40 (Suppl 1) A601
    PubMedSearch in Google Scholar
  • 23 Norman J G, Fink G W, Franz M G. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression.  Arch Surgery. 1995;  130 966-970
    PubMedSearch in Google Scholar
  • 24 Ollivier V, Parry G C, Cobb R R, deProst D, Mackman N. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocyclic cells and endothelial cells.  J Biol Chem. 1996;  271 20828-20835
    CrossrefPubMedSearch in Google Scholar
  • 25 Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Miyaguchi S, Takahashi K, Toyota T. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats.  Metabolism. 1998 a;  47 977-981
    CrossrefPubMedSearch in Google Scholar
  • 26 Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Sakata Y, Muto G, Muto Y, Takahashi K, Toyota T. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats.  Diabetologia. 1998 b;  41 1321-1326
    CrossrefPubMedSearch in Google Scholar
  • 27 Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine.  Diabetologia. 1996;  39 263-269
    CrossrefPubMedSearch in Google Scholar
  • 28 Sagara M, Satoh J, Zhu X P, Takahashi K, Fukuzawa M, Muto G, Muto Y, Toyota T. Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats.  Clin Immunol Immunopathol. 1994;  71 333-337
    CrossrefPubMedSearch in Google Scholar
  • 29 Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice.  J Clin Invest. 1989;  84 1345-1348
    PubMedSearch in Google Scholar
  • 30 Shteinberg D, Halak M, Shapiro S, Kinarty A, Sobol E, Lahat N, Karmeli R. Adbominal aortic aneurys and aortic occlusive disease: a comparison of risk factors and inflammatory response.  Euro J Vasc Endocasc Surg. 2000;  20 462-465
    PubMedSearch in Google Scholar
  • 31 Stephens J M, Pekala P H. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha.  J Biol Chem. 1991;  266 21839-21845
    PubMedSearch in Google Scholar
  • 32 Sushil K J, Krishnaswamy K, Gideon L, Robert M, Joseph Jr A B. Hyperketonemia increases tumor necrosis factor-α secretion in cultured U937 monocytes and type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency.  Diabetes. 2002;  51 2287-2293
    PubMedSearch in Google Scholar
  • 33 Tanaka S, Seino H, Satoh J, Fujii N, Rikiishi H, Zhu X P, Takahashi K, Sagara M, Nobunaga T, Toyota T. Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats.  Clin Immunol Immunopathol. 1992;  62 258-263
    CrossrefPubMedSearch in Google Scholar
  • 34 Yang X D, Tisch R, Singer S M, Cao Z A, Liblau R S, Schreiber R D, McDevitt H O. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process.  J Exp Med. 1994;  180 995-1004
    CrossrefPubMedSearch in Google Scholar
  • 35 Yokoyama H, Deckert T. Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis.  Diabetic Med. 1996;  13 313-320
    CrossrefPubMedSearch in Google Scholar
  • 36 Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kshi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy.  J Diabetes Comp. 2001;  15 257-259
    PubMedSearch in Google Scholar

Prof. M. D. Mitsuyasu Itoh

Division of Endocrinology & Metabolism, Department of Internal Medicine, Fujita Health University, School of Medicine

1 - 98 Dengakugakubo, Kutsukake

Toyoake, Aichi 470-1192

Japan

Phone: + 81562939242

Fax: + 81 5 62 95 18 79

Email: mituyasu@fujita-hu.ac.jp